Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients
Lei-Yun Wang,1,2 Jia-Jia Cui,1,2 Ao-Xiang Guo,1,2 Ji-Ye Yin1,2 1Department of Clinical Pharmacology, XiangYa Hospital, Central South University, Changsha, 2Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China Abstract: Compared wit...
Main Authors: | Wang LY, Cui JJ, Guo AX, Yin JY |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-01-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/clinical-efficacy-and-safety-of-afatinib-in-the-treatment-of-non-small-peer-reviewed-article-OTT |
Similar Items
-
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
by: Wu YL, et al.
Published: (2018-11-01) -
Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung
by: Lu S, et al.
Published: (2018-11-01) -
Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib
by: Lu S
Published: (2019-02-01) -
Palbociclib overcomes afatinib resistance in non-small cell lung cancer
by: Huijuan Nie, et al.
Published: (2019-01-01) -
Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways
by: Zhen Liu, et al.
Published: (2021-02-01)